BriaCell Therapeutics Corp. (TSX:BCT)
3.900
+0.100 (2.63%)
Jun 15, 2026, 3:58 PM EST
BriaCell Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is August - July.
Millions USD. Fiscal year is Aug - Jul.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 |
Cash & Equivalents | 6.88 | 10.49 | 0.86 | 21.25 | 41.04 | 57.27 |
Short-Term Investments | 15.92 | 7.37 | - | - | - | - |
Cash & Short-Term Investments | 22.8 | 17.87 | 0.86 | 21.25 | 41.04 | 57.27 |
Cash Growth | 83.02% | 1972.44% | -95.94% | -48.22% | -28.34% | 269412.45% |
Accounts Receivable | 2.59 | 2.06 | 2.79 | 5.7 | 0.02 | 0.01 |
Other Current Assets | - | - | - | - | 1.28 | 0.52 |
Total Current Assets | 25.39 | 19.93 | 3.65 | 26.95 | 42.35 | 57.8 |
Net Property, Plant & Equipment | 0.35 | 0.3 | 0.39 | - | - | - |
Other Intangible Assets | 0.17 | 0.18 | 0.2 | - | 0.23 | 0.25 |
Long-Term Investments | 0.75 | 0.52 | 0.42 | 0.22 | 0 | 0 |
Other Long-Term Assets | 0.41 | 0.72 | 1.21 | - | - | - |
Total Assets | 27.07 | 21.65 | 5.87 | 27.16 | 42.58 | 58.04 |
Accounts Payable | 2.17 | 3.28 | 7.17 | 1.12 | 0.46 | 0.21 |
Accrued Expenses | 1.42 | 0.69 | 0.29 | 0.68 | 0.48 | 0.34 |
Total Current Liabilities | 3.59 | 3.98 | 7.46 | 1.8 | 0.94 | 0.56 |
Other Long-Term Liabilities | 0.07 | 0.34 | 1.1 | 29.14 | 31.31 | 29.82 |
Total Long-Term Liabilities | 0.07 | 0.34 | 1.1 | 29.14 | 31.31 | 29.82 |
Total Liabilities | 3.66 | 4.32 | 8.56 | 30.94 | 32.25 | 30.37 |
Common Stock | 117.12 | 101.74 | 72.17 | 69.59 | 65.59 | 54.77 |
Additional Paid-in Capital | 41.42 | 28.04 | 11.03 | 7.42 | 5.23 | 2.18 |
Accumulated Other Comprehensive Income | -0.14 | -0.14 | -0.14 | -0.14 | -0.14 | -0.14 |
Retained Earnings | -134.34 | -111.76 | -85.44 | -80.65 | -60.35 | -29.14 |
Total Common Shareholders' Equity | 24.06 | 17.88 | -2.38 | -3.78 | 10.33 | 27.67 |
Minority Interest | -0.65 | -0.55 | -0.3 | - | - | - |
Shareholders' Equity | 23.41 | 17.33 | -2.68 | -3.78 | 10.33 | 27.67 |
Total Liabilities & Equity | 27.07 | 21.65 | 5.87 | 27.16 | 42.58 | 58.04 |
Net Cash (Debt) | 22.8 | 17.87 | 0.86 | 21.25 | 41.04 | 57.27 |
Net Cash Growth | 27.64% | 1972.44% | -95.94% | -48.22% | -28.34% | - |
Net Cash Per Share | 7.12 | 42.23 | 7.86 | 204.08 | 397.33 | 1900.69 |
Book Value | 24.06 | 17.88 | -2.38 | -3.78 | 10.33 | 27.67 |
Book Value Per Share | 7.51 | 42.26 | -21.72 | -36.27 | 100.00 | 918.39 |
Tangible Book Value | 23.89 | 17.7 | -2.58 | -3.78 | 10.1 | 27.43 |
Tangible Book Value Per Share | 7.46 | 41.82 | -23.54 | -36.27 | 97.77 | 910.24 |